left-arrow right-arrow pinterest facebook google_plus linkedin

Lung Cancer Trials

The following listings are our current trials. If you have questions or want to learn more about the trial, please contact us and provide the Methodist Health System Trial Code listed with the description.


Alliance A211401

Status: Recruiting | Phase III

Official Title: Reducing surgical complications in newly diagnosed lung cancer patients who smoke cigarettes.

Study Purpose: The purpose of this study is to see if complications after sugery can be reduced by helping patients stop smoking with a drug called varenicline (also called chantix) and using National Cancer Institute (NCI) Tobacco Quitline for counseling. This study will see how well the drug varenicline helps patients stop smoking by comparing it to a placebo (a pill that contains no active drug). Learn more


Alliance A221504

Status: Open | Phase II

Official Title: A Randomized, Double-Blind, Placebo-Controlled Pilot Study Of An Oral, Selective Peripheral Opioid Receptor Antagonist In Advanced Non-Small Cell Lung Cancer (Adenocarcinoma)

Study Purpose: To determine feasibility and safety of long-term administration of two doses of a peripheral opioid receptor antagonist in patients with advanced NSCLC receiving first-line pemetrexed-based chemotherapy. Learn more.


 
ECOG-ACRIN EA5142

Status: Recruiting | Phase III

Official Title: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab after Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Study Purpose: To evaluate whether adjuvant therapy with nivolumab will result in improved overall survival (OS) and/or disease-free survival (DFS) over standard observation in patients with Stage IB≥4cm, II and IIIA, NSCLC following surgical resection and standard adjuvant therapy. Learn more.


ECOG-ACRIN EA5162

Status: Recruiting | Phase II

Official Title: Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Mutations in EGFR

Study Purpose: To evaluate the best objective response rate of AZD9291 (osimertinib) among patients with EGFR exon 20 insertions. Learn more.


GO40241

Status: Recruiting |Phase III

Official Title: A Phase III, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients With Stage IB, II, IIIA, or Selected IIIB Resectable and Untreated Non-Small Cell Lung Cancer

Study Purpose: To evaluate the efficacy and safety of neoadjuvant treatment with atezolizumab in combination with platinum-based chemotherapy versus placebo plus platinum-based chemotherapy in patients with resectable non-small cell lung cancer. Learn more


RTOG 0538/CALGB 30610

Status: Recruiting | Phase III

Official Title: Phase III Comparison Of Thoracic Radiotherapy Regimens In Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin Or Carboplatin And Etoposide

Study Purpose: To determine if high dose radiotherapy given over a shorter period of time (3 weeks) is more effective than standard dose given over 7 weeks. Learn more.